Helix BioPharma Corp. Appoints New Board Director and Corporate Secretary to Support Financing and Nasdaq Uplisting

Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0) has announced the appointment of Zachary T. Stadnyk to its Board of Directors and Natalia L. Butterworth as Corporate Secretary, effective immediately. The appointments are part of the company's strategy to strengthen its capital markets and governance capabilities as it advances toward a planned Nasdaq listing through the Multijurisdictional Disclosure System (MJDS).

Mr. Stadnyk brings over 15 years of experience in biotechnology, capital markets, and public company leadership, including serving as Head of Life Sciences at the TSX and TSXV. He has led and supported over $100 million in institutional financings and contributed to strategic transactions such as the $435 million acquisition of The Supreme Cannabis Company by Canopy Growth. Ms. Butterworth is a seasoned corporate governance professional with more than 15 years of experience in governance and regulatory compliance across multiple jurisdictions, spanning pharmaceuticals, technology, and finance.

Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix BioPharma, stated: "As Helix continues to execute on its corporate and clinical development objectives, strengthening our capital markets and governance capabilities remains a key priority. These appointments come at an important time for Helix as we finalize the clinical protocol for L-DOS47 and actively prepare for a Nasdaq listing under the MJDS, including ongoing audit, governance, and capital markets readiness initiatives."

Zachary Stadnyk added: "I am excited to join Helix at such a pivotal stage in its development. The Company’s differentiated approach to addressing the tumor microenvironment and its clear path toward a Nasdaq listing creates a compelling opportunity. I look forward to supporting the team in advancing its capital markets strategy and unlocking value for its shareholders."

In connection with its ongoing capital markets and governance initiatives, Helix also announced it is relocating its registered and records office from Toronto, Ontario to Vancouver, British Columbia, aligning with the strengthening of its governance and capital markets infrastructure as it advances its Nasdaq uplisting strategy.

Helix BioPharma is an oncology company focused on hard-to-treat cancers, with a pipeline led by L-DOS47, a clinical-stage antibody-enzyme conjugate. The company is also advancing pre-IND candidates LEUMUNA and GEMCEDA. For more information, visit https://www.helixbiopharma.com/.